Literature DB >> 27876199

Comparison of homologous and heterologous prime-boost immunizations combining MVA-vectored and plant-derived VP2 as a strategy against IBDV.

Matías Richetta1, Evangelina Gómez2, María Soledad Lucero3, Silvina Chimeno Zoth4, María José Gravisaco5, Gabriela Calamante6, Analía Berinstein7.   

Abstract

Different immunogens such as subunit, DNA or live viral-vectored vaccines against Infectious Bursal Disease virus (IBDV) have been evaluated in the last years. However, the heterologous prime-boost approach using recombinant modified vaccinia Ankara virus (rMVA), which has shown promising results in both mammals and chickens, has not been tried against this pathogen yet. IBD is a highly contagious and immunosuppressive disease of poultry that affects mainly young chicks. It is caused by IBDV, a double-stranded RNA virus carrying its main antigenic epitopes on the capsid protein VP2. Our objective was to evaluate the immune response elicited by two heterologous prime-boost schemes combining an rMVA carrying the VP2 mature gene (rVP2) and a recombinant VP2 protein produced in Nicotiana benthamiana (pVP2), and to compare them with the performance of the homologous pVP2-pVP2 scheme usually used in our laboratory. The SPF chickens immunized with the three evaluated schemes elicited significantly higher anti-VP2 antibody titers (p<0.001) and seroneutralizing titers (p<0.05) and had less T-cell infiltration (p<0.001), histological damage (p<0.001) and IBDV particles (p<0.001) in their bursae of Fabricius when compared with control groups. No significant differences were found between both heterologous schemes and the homologous one. However, the rVP2-pVP2 scheme showed significantly higher anti-VP2 antibody titers than pVP2-rVP2 and a similar tendency was found in the seroneutralization assay. Conversely, pVP2-rVP2 had the best performance when evaluated through bursal parameters despite having a less potent humoral immune response. These findings suggest that the order in which rVP2 and pVP2 are combined can influence the immune response obtained. Besides, the lack of a strong humoral immune response did not lessen the ability to protect from IBDV challenge. Therefore, further research is needed to evaluate the mechanisms by which these immunogens are working in order to define the combination that performs better against IBDV. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Avian immune response; IBDV; Recombinant MVA; Subunit vaccine

Mesh:

Substances:

Year:  2016        PMID: 27876199     DOI: 10.1016/j.vaccine.2016.11.029

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.

Authors:  Chen-Yi Chiang; Mei-Yu Chen; Chia-Wei Hsu; Chia-Yeh Liu; Yu-Wen Tsai; Hung-Chun Liao; Jia-Ying Yan; Zih-Shiuan Chuang; Hsin-I Wang; Chien-Hsiung Pan; Chia-Yi Yu; Guann-Yi Yu; Ching-Len Liao; Shih-Jen Liu; Hsin-Wei Chen
Journal:  J Biomed Sci       Date:  2022-06-09       Impact factor: 12.771

2.  Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections.

Authors:  Martin C Langenmayer; Anna-Theresa Lülf-Averhoff; Silvia Adam-Neumair; Gerd Sutter; Asisa Volz
Journal:  Viruses       Date:  2018-08-24       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.